Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Machine Learning Identifies CHAF1A In Burkitt Lymphoma
23+ hour, 52+ min ago (252+ words) CHROMATIN assembly factor 1 subunit A (CHAF1A) has emerged as a candidate biomarker and potential therapeutic target in Burkitt lymphoma (BL), following an integrated gene-expression and machine-learning analysis. Researchers combined differential gene expression analysis with Random Forest machine learning to identify and…...
Julia Carnevale: Targeting P2RY8 and GNAS to Enhance T Cell Therapy in Solid Tumors - OncoDaily
12+ hour, 46+ min ago (559+ words) Julia Carnevale, Assistant Professor at the Gladstone-UCSF Institute of Genomic Immunology, shared on X: “Incredibly excited to share the first major paper from my lab Carnevale Lab led by postdoc Qi Liu Gladstone Institutes UCSF executing the first ever genome-wide in…...
Applied Sciences, Vol. 16, Pages 8159: Lycopene Nanoencapsulation and Cancer Treatment: A Systematic Review of Preclinical Evidence
17+ hour, 51+ min ago (507+ words) Lycopene is a natural compound with significant antitumor potential, although its poor bioavailability restricts its clinical application. To address this limitation, diverse nanoparticle-based delivery systems have been developed. This systematic review evaluated whether encapsulation improves the antitumoral efficacy of lycopene....
Scientists May Have Solved a Long-Standing Melanoma Treatment Mystery
1+ day, 11+ hour ago (655+ words) With cancer treatment, when a drug is given may matter almost as much as which drug is used. For years, melanoma researchers have faced a frustrating contradiction. Experiments suggested that periodically stopping certain targeted drugs might help keep resistant cancer…...
Iowa cancer researchers focus on white blood cell maturation, resiliency
2+ day, 1+ hour ago (738+ words) Researchers at Iowa’s public and private universities are focusing their efforts on white blood cells as they explore potential new cancer treatments. Iowa State University and Des Moines University faculty have published research on the growth and internal operations of…...
Finding what it takes to make a white blood cell could lead to new cancer treatment
1+ day, 22+ hour ago (635+ words) In leukemia’s most aggressive forms, the blood cell factories in our bone marrow falter. Instead of dividing and multiplying at their usual prolific pace, generating hundreds of billions of new cells daily, some precursor cells stall out at an immature…...
Immune imprinting in a changing world - Nature Immunology
2+ day, 10+ hour ago (192+ words) Nature Immunology (2026) Cite this article Research on SARS-CoV-2 shows that effective immunity can arise from a balance between recalling existing immune memory and generating new variant-specific antibodies, with important implications for designing future vaccines. Koutsakos, M. & Ellebedy, A. H. Immunity 56, 909–913 (2023). Cobey, S. Nat....
Author Correction: Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP
2+ day, 10+ hour ago (0+ words) ...
Biogen's felzartamab wins first global approval in China for multiple myeloma
2+ day, 14+ hour ago (137+ words) TJ Biopharma led clinical development and the NMPA registration filing in Greater China. Under a deal struck in April 2026, Biogen acquired exclusive Greater China commercialization rights for felzartamab, consolidating global rights to the asset. Biogen will handle commercial launch; TJ…...
Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
2+ day, 11+ hour ago (242+ words) The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise. Bristol Myers won its latest approval based on Phase 3 data showing the Zenbexus combination was superior…...